Valuation: Curis, Inc.

Market Cap 1.68M 1.49M 1.39M 1.27M 2.39M 161M 2.42M 16.85M 6.53M 82.52M 6.3M 6.17M 265M P/E 2026 *
-0.03x
P/E 2027 * -0.11x
Enterprise Value 1.68M 1.49M 1.39M 1.27M 2.39M 161M 2.42M 16.85M 6.53M 82.52M 6.3M 6.17M 265M EV / Sales 2026 *
-
EV / Sales 2027 * 0.18x
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Curis, Inc.

1 day-3.29%
1 week-3.19%
Current month-4.24%
1 month-40.49%
3 months-88.41%
6 months-92.70%
Current year-95.93%
1 week 0.8
Extreme 0.8
0.86
1 month 0.8
Extreme 0.8
1.35
Current year 0.8
Extreme 0.8
24.2
1 year 0.8
Extreme 0.8
34.4
3 years 0.8
Extreme 0.8
349.8
5 years 0.8
Extreme 0.8
3,236
10 years 0.8
Extreme 0.8
7,440
Manager TitleAgeSince
Chief Executive Officer 59 24/09/2018
Director of Finance/CFO 54 05/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 01/11/2003
Chairman 84 16/05/2017
Director/Board Member 71 03/06/2010
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 A Free

Chief Executive Officer

110,090 0.2824%
7/7/26 A Free

Director

6,800 0.0174%
7/7/26 A Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-3.29%-3.19%-97.57%-99.20% 1.68M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+79.01% 57.39B
+0.89%-0.63%+2.17%+35.99% 47.64B
+0.36%+0.81%+342.39%+748.97% 44.29B
-0.96%-4.50%+24.96%+31.45% 42.5B
-0.20%-0.77%+4.13%+111.69% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.01%+3.18%+31.19%+28.44% 28.53B
+0.05%-1.64%-8.14%-12.10% 24.34B
Average -0.16%-0.85%+37.80%+107.25% 39.05B
Weighted average by Cap. +0.39%-0.84%+57.09%+139.50%

Financials

2026 *2027 *
Net sales - 9.25M 8.22M 7.67M 6.99M 13.19M 889M 13.31M 92.83M 35.97M 455M 34.73M 33.98M 1.46B
Net income -52.02M -46.22M -43.14M -39.32M -74.15M -5B -74.84M -522M -202M -2.56B -195M -191M -8.2B -45.23M -40.19M -37.51M -34.19M -64.48M -4.35B -65.08M -454M -176M -2.22B -170M -166M -7.13B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
02/10/26 $0.8034 -3.29% 100,347
01/10/26 $0.8307 -0.99% 37,962
30/09/26 $0.8390 +1.21% 102,063
29/09/26 $0.8290 -0.29% 167,654
28/09/26 $0.8314 +0.18% 159,102
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8034USD
Average target price
42.67USD
Spread / Average Target
+5,210.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRIS Stock